On March 17, Huiyu Pharmaceuticals issued an announcement that the company recently received the "Drug Registration Certificate" for Melphalan Hydrochloride for Injection approved and issued by the State Drug Administration.

The registration classification of this drug is Class 4 chemical drugs, the specification is 50mg, and the drug validity period is 18 months. The registration certificate number is 2025S00720, and the drug approval number is National Medicine Standard H20253620. Melphalan is suitable for high-dose pretreatment and palliative treatment of patients with multiple myeloma.

According to Minnet data, the sales of melphalan hydrochloride for injection in terminal hospitals in urban public hospitals in China in the first half of 2024 were approximately 86 million yuan. The company is the second company deemed to have passed the consistency evaluation of generic drug quality and efficacy. It is expected that drugs that have passed the consistency evaluation will receive greater support in areas such as medical insurance payment and medical institution procurement. Although the company has carried out preliminary preparations for the launch of its products, due to competition from similar products and other market factors, there is uncertainty as to whether it can generate significant revenue in the future, which will not have a significant impact on the company's operating performance in the short term.

https://finance.eastmoney.com/a/202503173347698840.html